Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?

详细信息    查看全文

• 作者：Caela R. Miller^a ; ^{caela.r.miller.mil@mail.mil} ; ^{caelamiller@hotmail.com} ; Nicole P. Chappell^a ; Caitlin Sledge^a ; Charles A. Leath III^b ; Neil T. Phippen^c ; Laura J. Havrilesky^d ; Jason C. Barnett^a
• 关键词：Low risk gestational trophoblastic neoplasia ; Cost-effectiveness ; GOG0174 ; Actinomycin D ; Methotrexate
• 刊名：Gynecologic Oncology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：144
• 期：1
• 页码：125-129
• 全文大小：534 K
• 卷排序：144

文摘

Use of Act-D over MTX had an incremental cost effectiveness ratio (ICER) of $56,215. With sensitivity analysis any toxicity associated with Act-D inflated the ICER. If goal is avoidance of multi-agent chemotherapy, any MTX regimen outperformed Act-D.